Oncodex Injection

About Oncodex 4 mg/2 ml Injection

Oncodex comes as a injection with 4 mg/2 ml of Ondansetron, from Jayson Pharmaceuticals Ltd. It is an anti-emetic medicine that blocks the initiation of the vomiting reflex.

There are 74 brands of Ondansetron listed in Bangladesh. The lowest listed price is Periset 16 mg Suppository at ৳ 1 per unit.

What is Oncodex 4 mg/2 ml Injection?

Oncodex 4 mg/2 ml injection is a medicine made by Jayson Pharmaceuticals Ltd. Ondansetron works by blocking a natural substance in the body that can trigger the vomiting reflex. Anti-emetics are medicines used to help manage nausea and vomiting. The dose and course are decided by the doctor, and the injection is given by a healthcare professional.

Uses of Oncodex

It is an anti-emetic medicine that blocks the initiation of the vomiting reflex. Oncodex 4 mg/2 ml is used to prevent nausea and vomiting linked to cancer chemotherapy and radiotherapy. It is not for self-administration. Your doctor will decide if this medicine is suitable for you.

How to use Oncodex

Oncodex is an injection, so it is given by a doctor, nurse or other trained healthcare professional. Do not inject it yourself unless a doctor has shown you how. It is not for self-administration at home. The dose and schedule are determined by the doctor based on the reason it is being given and the patient's response. The doctor decides the dose, how it is given and how long the course lasts.

Side effects of Oncodex

Rarely, serious allergic reactions, breathing problems, fast heartbeat, chest pain, low potassium, and shortness of breath have been reported. If you notice any severe or worrying symptoms, contact your doctor right away. If you experience any side effects, contact your doctor. Tell your doctor if any side effect bothers you or does not go away. Tell your doctor if you notice any side effect, especially one that worries you.

Safety and precautions

Tell the doctor about allergies to other similar medicines, and about any stomach or bowel problems, especially after abdominal surgery, because this medicine can hide signs of a developing problem. There are no adequate, well-controlled studies in pregnant women, so ask your doctor before use if you are pregnant, planning pregnancy or breastfeeding. It should not be used with apomorphine. The doctor decides if it is suitable for you.

Frequently asked questions

What does Oncodex treat?

It is an anti-emetic medicine that blocks the initiation of the vomiting reflex. Oncodex 4 mg/2 ml is used to prevent nausea and vomiting linked to cancer chemotherapy and radiotherapy.

How should I take Oncodex?

Oncodex is an injection, so it is given by a doctor, nurse or other trained healthcare professional. Do not inject it yourself unless a doctor has shown you how.

What are the side effects of Oncodex?

Rarely, serious allergic reactions, breathing problems, fast heartbeat, chest pain, low potassium, and shortness of breath have been reported. If you notice any severe or worrying symptoms, contact your doctor right away.

Can I use Oncodex in pregnancy or while breastfeeding?

Tell the doctor about allergies to other similar medicines, and about any stomach or bowel problems, especially after abdominal surgery, because this medicine can hide signs of a developing problem. There are no adequate, well-controlled studies in pregnant women, so ask your doctor before use if you are pregnant, planning pregnancy or breastfeeding.

Indications

Ondansetron is a serotonin subtype 3 (5-HT3) receptor antagonist indicated:
  • Prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy.
  • Prevention and treatment of post-operative nausea and vomiting.
  • Prevention of radiotherapy-induced nausea and vomiting.

Pharmacology

Ondansetron is a potent, highly selective 5HT3 receptor-antagonist. Its precise mode of action in the control of nausea and vomiting is not known. Chemotherapeutic agents and radiotherapy may cause release of 5HT in the small intestine initiating a vomiting reflex by activating vagal afferents via 5HT3 receptors. Ondansetron blocks the initiation of this reflex. Activation of vagal afferents may also cause a release of 5HT in the area postrema, located on the floor of the fourth ventricle, and this may also promote emesis through a central mechanism. Thus, the effect of ondansetron in the management of the nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy is probably due to antagonism of 5HT3 receptors on neurons located both in the peripheral and central nervous system. The mechanisms of action in post-operative nausea and vomiting are not known but there may be common pathways with cytotoxic induced nausea and vomiting.

Dosage & Administration

Chemotherapy-Induced Nausea and Vomiting-
Adults, Pediatric patients (6 months to 18 years):
  • 8 mg tablet/orodispersible tablet: Three 0.15 mg/kg doses, up to a maximum of 16 mg per dose.
  • 4 mg orodispersible tablet: Three 0.15 mg/kg doses, up to a maximum of 16 mg per dose.
  • Injection: Three 0.15 mg/kg doses, up to a maximum of 16 mg per dose, infused intravenously over 15 minutes.
Radiotherapy-Induced Nausea and Vomiting-
Adults:
  • 8 mg tablet/orodispersible tablet: Initial Dose: 8 mg orally 1 to 2 hours before radiotherapy. Post Radiotherapy: 8 mg orally every 8 hours for up to 5 days after a course of treatment.
  • 4 mg orodispersible tablet: Three 0.15 mg/kg doses, up to a maximum of 16 mg per dose.
  • Injection: Three 0.15 mg/kg doses, up to a maximum of 16 mg per dose, infused intravenously over 15 minutes.
Postoperative Nausea and Vomiting-
Adults:
  • 8 mg tablet/orodispersible tablet: 16 mg given as two 8 mg tablets
  • 4 mg orodispersible tablet: 16 mg
  • Injection: 4 mg
Pediatrics (>40 kg): Injection: 4 mg
Pediatrics (40 kg): Injection: 0.1 mg/kg

Chemotherapy-induced Nausea and Vomiting-
Adults/Geriatric/Child of 12 years or over:
  • Highly emetogenic cancer chemotherapy: 30 ml (24 mg) Ondansetron Oral Solution administered 30 minutes before start of emetogenic chemotherapy.
  • Moderate emetogenic cancer chemotherapy: 10 ml (8 mg) Ondansetron Oral Solution administered 30 minutes before start of emetogenic chemotherapy. A further 10 ml dose should be administered after 8 hours of the first dose. One 10 ml dose should be administered twice a day (every 12 hours) for 1-2 days after completion of chemotherapy.
Pediatric (4-11 years): 5 ml (4 mg) Ondansetron Oral Solution should be taken 30 minutes before the start of chemotherapy. The other 2 doses should be taken 4 and 8 hours after the first dose. Then 5 ml oral solution should be administered 3 times a day (every 8 hours) for 1-2 days after completion of chemotherapy.


Oral solution:

Radiotherapy induced Nausea and Vomiting (Adults/Geriatric/Child of 12 years or over):
  • The recommended oral dosage: 10 ml (8 mg) Ondansetron Oral Solution 3 times daily.
  • For total body irradiation: 10 ml (8-mg) Ondansetron Oral Solution should be administered 1 to 2 hours before each fraction of radiotherapy administered each day.
  • For single high-dose fraction radiotherapy to the abdomen: one 10 ml Ondansetron Oral Solution should be administered 1 to 2 hours before radiotherapy, with subsequent doses every 8 hours after the first dose for 1 to 2 days after completion of radiotherapy.
  • For daily fractionated radiotherapy to the abdomen: 10 ml (8-mg) Ondansetron Oral Solution should be administered 1 to 2 hours before radiotherapy, with subsequent doses every 8 hours after the first dose for each day radiotherapy is given.
Postoperative Nausea and Vomiting (Adults/Geriatric/Child of 12 years or over):
  • 20 ml (16 mg) Ondansetron Oral Solution 1 hour before induction of anesthesia


Oral Soluble Film:

Prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy:
  • Adult oral dose: 24 mg given successively as three 8 mg films 30 minutes before the start of chemotherapy.
Prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy:
  • Adults and pediatric patients 12 years of age and older: One 8 mg film 30 minutes before chemotherapy followed by an 8 mg dose 8 hours later. Administer one 8 mg film twice a day (every 12 hours) for 1 to 2 days after completion of chemotherapy.
  • Pediatric patients 4 through 11 years of age: One 4 mg film three times a day. Administer the first dose 30 minutes before chemotherapy, with subsequent doses 4 and 8 hours later. Administer one 4 mg film three times a day (every 8 hours) for 1 to 2 days after completion of chemotherapy.
  • Prevention of nausea and vomiting associated with radiotherapy: The adult dosage is one 8 mg film three times a day.
  • Postoperative nausea and vomiting: The adult dose is 16 mg given successively as two 8 mg films 1 hour before anesthesia.

Interaction

Ondansetron does not itself appear to induce or inhibit the cytochrome P-450 drug-metabolizing enzyme system of the liver. Because Ondansetron is metabolized by hepatic cytochrome P-450 drug-metabolizing enzymes, inducers or inhibitors of these enzymes may change the clearance and hence, the half-life of Ondansetron. On the basis of available data, no dosage adjustment of Ondasetron is recommended for patients on these drugs.

Contraindications

Contraindicated in patients known to have hypersensitivity to the drug or any of its components. Concomitant use of apomorphine.

Side Effects

Frequently reported adverse events were headache, constipation and diarrhea, but the majority have been mild or moderate in nature. In chemotherapy-induced nausea and vomiting, rash has occurred in approximately 1% of patients receiving Ondansetron. There also have been reports to a sensation of flushing or warmth, hiccups and liver enzyme abnormalities. Rare cases of anaphylaxis, brochospasm, tachycardia, angina (chest pain), hypokalemia, shortness of breath have also been reported, except for bronchospasm and anaphylaxis, the relationship to Ondansetron is unclear. There have been no evidence to extrapyramidal reactions, in rare case oculogyric crisis appearing alone, as well as with other dystonic reactions without definitive clinical evidence. In case of PONV, with the exception of headache, rates of these events were not significantly different in the Ondansetron and placebo groups.

Pregnancy & Lactation

Carcinogenic effects were not seen in 2-year studies in rats and mice with oral Ondansetron doses up to 10 and 30 mg/kg per day, respectively. Ondansetron was not mutagenic in standard tests for mutagenicity. Oral administration of Ondansetron up to 15 mg/kg per day did not affect fertility or general reproduction performance of male and female rats.

Reproduction studies have been performed in pregnant rats and rabbits at daily oral doses up to 15 and 30 mg/kg per day, respectively, and have revealed no evidence of impaired fertility or harm to the fetus due to Ondansetron. There are, however, no adequate and well-controlled studies in pregnant women. Ondansetron is excreted in the breast milk of rats. So caution should be exercised when Ondansetron is administered to a nursing women.

Precautions & Warnings

Hypersensitivity reactions have been reported in patients who have exhibited hypersensitivity to other selective 5-HT3 receptor antagonists. Ondansetron is not a drug that stimulates gastric or intestinal peristalsis. It should not be used instead of nasogastric suction. The use of Ondansetron in patients following abdominal surgery or in patients with chemotherapy-induced nausea and vomiting may mask a progressive ileus and/or gastric distension.

Storage Conditions

Store at temperature not exceeding 30ºC in a dry place. Protect from light and moisture.

Alternative brands of Ondansetron

Other brands with the same generic name, cheapest first.

See all 74 brands

Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.